Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-E-CART in Advanced Solid Tumors
NCT05745454Phase 1Not yet recruiting
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of HER2-E-CAR-T in solid tumor. Primary endpoint: Occurrence of Adverse event rate up to 2 years. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
HER2-E-CAR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05745454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745454.